Related Experiment Videos
Interferon prophylaxis of hepatic carcinoma
R Voiosu1, L Dimitriu, P Dragomir
1N. Gh. Lupu Hospital, Department of Gastroenterology 19-21, Sos. Stefan cel Mare, 72202 Bucharest, Romania.
Summary
This review highlights hepatic carcinoma (liver cancer) in digestive oncology, discussing oncogenesis mechanisms and viral hepatitis (Hepatitis B, C, D) roles. It examines interferon prophylaxis and presents long-term hospital data on viral hepatitis, cirrhosis, and liver cancer.
Area of Science:
- Hepatology
- Digestive Oncology
- Virology
Background:
- Hepatic carcinoma is a significant concern in digestive oncology.
- Understanding oncogenesis mechanisms and viral etiologies is crucial for accurate diagnosis and treatment.
- Hepatitis B virus (HBV), Hepatitis C virus (HCV), and coinfections play a role in liver disease progression.
Purpose of the Study:
- To emphasize the importance of hepatic carcinoma within digestive oncology.
- To review current hypotheses on liver cancer oncogenesis.
- To analyze the role of viral hepatitis infections and interferon prophylaxis in hepatic carcinoma development.
Main Methods:
- Literature review of studies on viral hepatitis (HBV, HCV, HDV) and oncogenesis.
- Statistical analysis of diagnosed cases of chronic viral hepatitis, cirrhosis, and hepatic carcinoma.
- Data collected from "N.Gh.Lupu" Hospital over a 20-year period.
Main Results:
- Viral infections, particularly HBV and HCV, are significant contributors to chronic hepatitis, cirrhosis, and hepatic carcinoma.
- Coinfections with HBV/HCV and HBV/HDV increase disease severity.
- Interferon prophylaxis may play a role in managing viral hepatitis-related liver diseases.
Conclusions:
- Accurate designation and management of hepatic carcinoma cases are vital.
- Viral hepatitis remains a primary driver for a substantial proportion of liver cancer cases.
- Long-term hospital data underscore the epidemiological impact of viral hepatitis on liver health and cancer incidence.